At the beginning of September, a large number of enterprises in the pharmaceutical field received tens of millions of yuan in financing

【Pharmaceutical Network Industry Dynamics】Since the beginning of this year, domestic financing in the fields of medicine and medical health has been hot
.

According to incomplete statistics in the industry, in early August alone (1 to 7), a total of 42 investment and financing incidents occurred in the domestic medical and health field, and from the perspective of a single disclosed amount, many of them raised more than 100 million US dollars
.

At present, the time has come to September, from the current situation of the industry, in order to promote innovative research and development, pharmaceutical enterprise financing is continuing to be hot, and a large number of enterprises have obtained tens of millions of yuan of financing
.

Meisai Biotech completed tens of millions of financing On September 2, Hangzhou Meisai Biomedical Technology Co.
, Ltd.
announced the completion of a new round of financing
of tens of millions of yuan.

This round of financing is led exclusively by Juming Venture Capital, and the old shareholder Kaifeng Venture Capital continues to invest, and the funds raised will be mainly used for the research and development, product registration and clinical declaration
of existing new targets and new product pipelines.

According to public information, Meisai Bio is the first emerging biotechnology enterprise in China to focus on the development of new targets of macrophages in the tumor microenvironment, and drugs for macrophages can enhance the engulfment of macrophages on tumor cells, recruit and activate downstream effector T cells, realize the reprogramming of the tumor immune microenvironment, and achieve the purpose of
treating or even completely curing solid tumors.

On September 2, Neukio Biotherapeutics announced that it had completed an A-1 round of $50 million
.

The round of financing is led by CD Capital, followed by Yahui Investment and Kuanyu Capital, and the existing shareholders Eli Lilly Asia Fund, Sherpa Capital and IDG Capital continue to invest additionally, with Gelu Capital acting as the exclusive financial advisor
.

It is understood that Xingyi Ang is an innovative biomedical company focusing on the development and industrialization of a new generation of immune cell products, and is committed to providing clinically valuable treatment for cancer patients
around the world.

The funding will play an important role
in accelerating the preclinical validation and clinical development and team recruitment of CAR-NK, a general-purpose spot cell therapy product derived from iPSC.

WuXi Borui Completes Nearly RMB300 Million Series A Financing On September 2, WuXi Borui Biotechnology Co.
, Ltd.
announced the completion of nearly RMB300 million Series A financing
.

The financing was led by Sequoia China, followed by Sunshine Ronghui, Tianfu Sanjiang Capital, and Puhua Capital
.

After this financing, the company will accelerate the clinical development and registration of multiple self-developed
pipelines.

As a radionuclide-targeted drug developer, WuXi Pharma Focuses on the research and development and clinical application
of radionuclide-targeted drugs.

On September 1, Demote Biotechnology (Zhuhai) Co.
, Ltd.
completed a round of financing of nearly 100 million yuan Pre-A, jointly led by Sequoia Envision Carbon Neutral Fund and Envision Technology Group, and the old shareholder Sequoia China Seed Fund continued to raise, with Weizhen Capital acting as the exclusive financial advisor
.

This round of financing will be used for the construction of "smart light carbon factories" and the development
of next-generation pipelines.

Demote is committed to providing solutions based on microalgae technology, and currently develops and produces products such as functional lipids and proteins, mainly in the fields
of food, dietary supplements, cosmetics and animal nutrition.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.